[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU648892B2 - Dentifrice composition - Google Patents

Dentifrice composition Download PDF

Info

Publication number
AU648892B2
AU648892B2 AU16309/92A AU1630992A AU648892B2 AU 648892 B2 AU648892 B2 AU 648892B2 AU 16309/92 A AU16309/92 A AU 16309/92A AU 1630992 A AU1630992 A AU 1630992A AU 648892 B2 AU648892 B2 AU 648892B2
Authority
AU
Australia
Prior art keywords
stannous
composition
ions
antioxidant
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16309/92A
Other versions
AU1630992A (en
Inventor
Philip Christopher Waterfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Original Assignee
Unilever PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC filed Critical Unilever PLC
Publication of AU1630992A publication Critical patent/AU1630992A/en
Application granted granted Critical
Publication of AU648892B2 publication Critical patent/AU648892B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20Halogens; Compounds thereof
    • A61K8/21Fluorides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

The present invention relates to a dentifrice composition comprising a stannous compound that releases stannous ions in the composition such as stannous fluoride or stannous pyrophosphate. These stannous ions can be converted in the composition into the inactive stannic ions, and to prevent such conversion according to the present invention an antioxidant is incorporated into the composition, such as butylated hydroxyanisole, butylated hydroxytoluene and ethyl vanillin.

Description

648892
AUSTRALIA
PATENTS ACT 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT INVENTION TITLE: DENTIFRICE COMPOSITION .too 0.00 .0 too.
0%.
0 0 0 0 0:0.
0 0 to .00 to Go 0.00 0 The following statement is a full description of this invention, including the best method of performing it known to me:- I .4r 1 J 7025 (R) "DENTIFRICE COMPOSITIONS" The present invention relates to dentifrice compositions containing stannous compounds.
There have been many proposals in the prior art to incorporate stannous compounds into oral health care products for the purpose of achieving particular clinical benefits such as caries prevention, plaque 1 0 control or the reduction of gingivitis. These stannous compounds are compounds which, upon association with water, are capable of yielding stannous ions, as it is actually the stannous ion which is active against oral bacteria.
However, the incorporation of stannous compounds into dentifrice compositions presents problems in that the stannous ions tend to react with other components of the dentifrice composition to form insoluble stannous 20 compounds, which reduces the effective amount of stannous ions in the composition and thus renders the stannous compound less efficacious. In addition, the active stannous ion is particularly prone to oxidation, e.g. by air or an oxidizing agent, the stannous ion being converted thereby into the inactive stannic form.
In GB-A-804,486 it is proposed to overcome the problem that stannous ions react with other components of a dentifrice composition by using a slightly soluble stannous compound, e.g. stannous pyrophosphate, thus maintaining a "reservoir" of stannous tin in the form of an undissociated stannous compound which replenishes stannous ions that have reacted with other components of the dentifrice composition.
We have found, however, that the inclusion of such slightly soluble stannous compounds, e.g. stannous J 7025 (R) pyrophosphate, still gives rise to the formation of inactive stannic compounds.
According to the present invention it has now been found that the conversion of stannous ions in a dentifrice composition into inactive stannic ions can be significantly reduced or prevented by the inclusion in the dentifrice composition of an antioxidant which is a radical inhibitor. Since dentifrice compositions do not i0 normally contain an oxidizing agent and are usually packed in a closed container, it was quite unexpected that the use of an antioxidant of the radical inhibitortype did significantly reduce and prevent the S conversion of stannous ions into stannic ions in such a dentifrice composition.
Consequently, in its broadest aspect, the present invention embraces a dentifrice composition which comprises an effective amount of a stannous compound 20 capable of yielding stannous ions upon association with water, and an effective amount of an antioxidant which is a radical inhibitor capable of reducing or preventing the conversion of the stannous ions in the dentifrice i S composition into stannic ions.
The stannous compounds which are suitable for inclusion in dentifrice compositions are known per se. Typical examples of suitable stannous compounds are stannous compounds with inorganic or organic counter-ions. It can be a highly soluble stannous salt, or it can be a sparingly soluble stannous salt. Highly soluble stannous salts ere e.g. stannous fluoride, stannous chloride, stannous chloride fluoride, stannous acetate, sodium stannous fluoride, potassium stannous fluoride, stannous hexafluorozirconate, stannous sulphate, stannous tartrate, stannous gluconate, etc. Of these highly soluble stannous salts, stannous fluoride is the preferred stannous salt.
J 7025 (R) Sparingly soluble stannous salts are e.g. stannous pyrophosphate, stannous metaphosphate, stannous oxalate, stannous phosphate, etc. Stannous pyrophosphate is a preferred sparingly soluble stannous salt. Mixtures of various highly soluble stannous salts may also be used, as well as mixtures of various sparingly soluble stannous salts and mixtures of highly and sparingly soluble stannous salts. A preferred mixture is the 10 mixture of stannous fluoride and stannous pyrophosphate.
g In general, the stannous salt is used in such an amount S in the oral composition that there is an effective amount of active dissolved stannous ions available in the composition to achieve an anti-caries, antigingivitis or anti-plaque efficacy. For the highly soluble stannous salts, this amount will generally range from 0.01-10%, preferably from 0.02-5%, and particularly 20 preferably from 0.1-3% by weight of the oral composition. As regards the sparingly soluble stannous salts, these ranges are 0.05-10%, preferably and Sparticularly preferably 0.1-3% by weight of the oral Scomposition.
Antioxidants which are radical inhibitors are known per se. Both synthetically made or naturally occurring antioxidants are suitable in the present invention.
Typical examples of suitable antioxidants in the present invention are propyl gallate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethyl vanillin, rosemary oil, lecithin, vitamin E, rutin, morin, fisetin and other bioflavonoids. Mixtures of various antioxidants can also be used.
The antioxidant is used in an effective amount to significantly reduce or prevent the conversion of stannous ions into stannic ions. In general, low amounts J 7025 (R) of the antioxidants are already sufficient. Thus, the amount may range from 0.001-2%, usually from 0.015-1.5%, and preferably from 0.02-1% by weight of the dentifrice composition. Naturally, within the above framework the type of antioxidant and the level thereof will also be governed by ecological and safety approval factors.
Preferred antioxidants are BHA, BHT, and ethyl vanillin.
10 The oral composition of the present invention may contain an orally acceptable medium which contains usual additional ingredients in conventional amounts, depending upon the final form of the composition, i.e. a dentifrice, a mouthwash, a gel and the like. Thus, as dentifrice it will usually comprise an abrasive cleaning agent in an amount of from 3-75% by weight. Suitable abrasive cleaning agents are milled or unmilled particulate aluminas; silica xerogels, hydrogels and aerogels and precipitated particulate silicas; calcium 20 pyrophosphate; insoluble sodium metaphosphate; calcium carbonate; dicalcium orthophosphate; particulate hydroxyapatite and so on.
99 Furthermore, the dentifrice may contain a liquid phase comprising water and a humectant in various relative amounts, in an amount of 10-99% by weight. Typical humectants are glycerol, sorbitol, polyethylene glycol, polypropylene glycol, propylene glycol, hydrogenated partially hydrolyzed polysaccharides and so on.
Binders or thickening agents such as sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, xanthan gums, Irish moss, gum tragacanth, finely divided silicas and hectorites may also be included in the dentifrice in an amount of by weight.
J 7025 (R) Another conventional ingredient in a dentifrice is an organic surfactant such as soap, an anionic, nonionic, cationic, ampholytic and/or a zwitterionic synthetic surfactant in an amount of 0.2-5% by weight.
When the composition is in the form of a mouthwash, it will usually contain an alcohol, a solubilizer, and when in the form of a gel, it will usually contain a thickening agent.
S: Various other optional ingredients may be included in the compositions of the invention, such as flavouring agents, sweetening agents such as sodium saccharinate, I* whitening agents such as titanium dioxide or zinc oxide, preservatives, vitamins such as vitamin C and E, other anti-plaque agents such as zinc salts, e.g. zinc citrate, copper salts, sanguinarine, allantoin, paminobenzoic acid derivatives, hexetidine, chlorhexidine, 3-(4-propylheptyl)-4-(2-hydroxyethyl)- 20 morpholine, anti-bacterial agents such as Triclosan (2',4,4'-trichloro-2-hydroxy-diphenyl ether), anticalculus agents such as di- and/or tetra-alkali metal pyrophosphates, pH-adjusting agents, colouring agents, anti-caries agents such as casein, casein digests, urea, calcium glycerophosphates, sodium trimetaphosphate, sodium fluoride and monosodium fluorophosphate, anti-staining compounds such as silicone polymers, anti-inflammatory agents such as substituted salicylanilides, plant extracts, desensitizing agents for sensitive teeth such as potassium nitrate and potassium citrate, polymers such as polyvinyl methyl ether-maleic anhydride co-polymers and so on.
The present invention will now be further illustrated by the following Examples.
6 J 7025 (R) EXAMPLE 1 Five aqueous solutions of stannous fluoride, sodium lauryl sulphate and propyl gallate were prepared. The levels are listed below Solution SnF2 SLS Propyl Gallate 1 0.5% 1.5% 0% (Control) 2 0.5% 1.5% 0.25% 10 3 0.5% 1.5% 4 0.5% 1.5% 0.75% 5 0.5% 1.5% 1.00% All quantities are w/v.
The solutions were made up in distilled water that had been purged with dry nitrogen gas for 1 hour prior to use. The SLS was added to solubilize the propyl gallate.
20 The solutions were left at 20 0 C for 5 days. After this period, the solutions contained varying amounts of a white precipitate. Small aliquots of the whole solution were taken and analyzed, using Mossbauer Spectroscopy.
SAfter 10 days, solutions 1 and 5 were analyzed by Mossbauer Spectroscopy again.
In addition to Mossbauer Spectroscopy, the solutions were analyzed after 5 days for soluble stannous content by polarography. However, unlike the samples taken for Mossbauer analysis, the samples for polarographic analysis were centrifuged first (3000 rpm, 30 minutes) to remove the flocculent white precipitate.
Results: J 7025 (R) Polarographic Analysis: Solution So 1 2 3 4 luble Stannous Levels/ppm 905 1271 1691 1786 1861
S
S
S.
S.
Mossbauer Analysis: 5 DAYS Sn(II) Solution 1 2 3 4
I.S.
3.15 3.16 3.16 3.19 3.14 3.11 3.14 0.S.
1.88 1.79 1.80 1.77 1.98 1.98 1.80 Sn(IV)
I.S.
-0.32 -0.52 -0.57 -0.53 -0.58 -0.32 -0.57 Area of Sn(IV) Peak 6 4 4 54 6
DAYS
1 All figures given in Mossbauer errors I.S. Isomer Shift; mmsec-1 0.05 mmsec-1 Q.S. Quadrupole Split.
It is clear from the polarographic analysis that increasing levels of propyl gallate inhibited the loss of soluble stannous from solution. The polarograph, however, only tests the stannous components in solution.
The Mossbauer spectra showed that with no propyl gallate present (solution at least 34% of the total tin was Sn(IV) after 5 days and 54% Sn(IV) at 10 days. Even with only 0.25% of propyl gallate, after 5 days, there was only approximately 6% of Sn(IV) and this level of Sn(IV) contamination was present in the starting materials anyway.
J 7025 (R) These data showed that the propyl gallate was inhibiting the oxidation of Sn(II) to Sn(IV).
EXAMPLE 2 A series of 6 toothpastes have been formulated, containing different antioxidants. The formulations are listed below. The pastes were stored at 50 0 C for 1.7 months and analyzed, using Mossbauer Spectroscopy.
S.
Paste Silica xerogel Silica aerogel Sorbitol (70%) Polyethylene glycol (MW 1500) Xanthan gum Saccharin Sodium fluoride 20 Benzoic acid Titanium dioxide Sodium lauryl sulphate Stannous pyrophosphate Zinc citrate Flavour Special progallin Propyl gallate
BHA
Rosemary oil extract Ethyl vanillin
BHT
Water 14.67 14.67 9.43 9.43 46.98 46.98 14.67 14.67 9.43 9.43 46.98 46.98 5.24 0.63 0.24 0.34 0.1965 5.24 0.63 0.24 0.34 0.1965 5.24 0.63 0.24 0.34 0.1965 5.24 0.63 0.24 0.34 0.1965 14.67 9.43 46.98 5.24 0.63 0.24 0.34 0.196E 14.67 9.43 46.98 5.24 0.63 0.24 0.34 5 0.1965 1.04 1.04 1.04 1.04 1.04 1.04 1.5 1.5 1.5 1.5 1.5 1.0 0.5 1.0 1.0 0.5 1.0 1.0 0.5 1.0 1.0 0.5 1.0 1.0 0.5 1.0 0.05 0.05 0.07 1 .00 1.00 0.03 17.24 17.24 17.23 17.14 17.14 17.24 Total 100.00 100.00 100.00 100.00 100.00 100.00 J 7025 (R) Results: Antioxidant in Paste I.S.
Progallin 2.95 3.14 Propyl 2.93 Gallate 3.17 (0.05%) Butylated 2.94 Hydroxyanisole 3.14 (0.07%) Rosemary Oil 2.95 Extract 3.14 Ethyl Vanillin 2.94 3.15 Butylated 2.94 HydroxyToluene 3.15 (0.03%) Sn(II) 2.13 1.75 2.11 1.81 2.10 1.77 2.09 1.77 2.09 1.79 2.10 1.78 Sn(IV)
I.S.
-0.15 -0.18 -0.24 -0.21 -0.19 Area of Sn(IV) Peak
S
*5 9
S
S
-0.22 Again, these data showed that the antioxidants inhibited the oxidation of Sn(II) to Sn(IV).
EXAMPLE 3 A series of nine toothpastes having the following formulations were stored for nine months at 370C, and the amount of Sn (IV) was determined using Mossbauer spectroscopy. The amount of soluble Sn (II) was determined by polarographic analysis. Figures I and II show the results,, These results show, that the inclusion of antioxidants have a beneficial effect on the stability of Sn (II), even in the presence of an additional 0.5% citrate, of which it is known that it can exert a solubilizing effect on stannous ions in certain formulations.
*5*
S
*5 *SS S S *5 S S S *5 S J 7025 (R) Paste Control BT/CIT EV EV/CIT BA/CIT BAIBTICIT BA BA/BT Silica xeroget Silica aerogeL Sorbito (70%) PotyethytenegtycoL (MW 1 '500) Xanthan gum Titanium doxide Saccharin sodium fluoride fodi um Laurytsutphate S tannous pyrophosph atce Zinc citrate Fl avour B R A B H T EthyL vanillin sodium citrate C it r ic a c id Water 10.00 9.00 45.00 5.00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 10.00 9.00 45.00 5.00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 10.00 9.00 45.00 5.00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 0.03 10.00 9.00 45.00 5 .00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 0.80 10.00 9.00 45.00 5.00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 0.80 0.325 0. 175 10.00 9.00 45.00 5 .00 1 .20 1 .00 0. 13 0.25 1 .50 1 .00 0.50 1 .00 0.07 0.325 0. 175 10.00 9.00 45.00 5.00 1 .20 1 .00 0.13 0.25 1 .50 1 .00 0.50 1 .00 0.07 0.03 0.325 0. 175 23.820 10.00 9.00 45.00 10.00 9.00 45. 00 5.00 5 .00 1 .20 1 1 .00 1 .00 0. 13 0. 13 0.25 0. 1 .50 1 1 .00 1 .00 0.50 0.50 1 .00 1 .00 0.07 0.07 0. 03 24.35 24.32 0.03 0.325 0.175 24.42 23.890 24.39 23.62 23.120 23.850

Claims (6)

1. A dentifrices composition comprising from 0.01 10% by weight of a stannous compound, capable of yielding stannous ions upon association with water, characterised in that the composition further comprises an antioxidant whcih is a radical inhibitor capable of reducing or preventing the conversion of the stannous ions in the dentifrice into stannic ions.
2. A composition according to claim 1, characterised in that the antioxidant is selected from the group consisting of propyl gallate, butylated hydroxyanisole, butylated hydroxytoluene, ethyl vanillin, rosemary oil, lecithin, vitamin E, rutin, morin, fisetin and mixtures thereof.
3. A composition according to claim 2, characterised in that the antioxidant is butylated hydroxyanisole, butylated hydroxytoluene or ethyl vanillin.
4. A composition according to claims 1-3, characterised in that the antioxidant is present in an amount of 0.001 2% by weight.
5. A composition according to claim 4, characterised in that the antioxidant is present in an amount of 0.02 1 by weight.
6. A composition according to claims 1-5, characterised in that the stannous compound is stannous flouride, stannous pyrophosphate or mixtures thereof. DATED this 17th February 1994 Signed for and on behalf of UNILEVER PLC ;y UNILEVER AUSTRAL1,a LIMITED SP.L. Cox, Alternate Director ABSTRACT The present invention relates to a dentifrice composition comprising a stannous compound that releases stannous ions in the composition such as stannous fluoride or stannous pyrophosphate. These stannous ions can be converted in the composition into the inactive stannic ions, and to prevent such conversion according to the present invention an antioxidant is incorporated into the composition, such as butylated hydroxyanisole, butylated hydroxytoluene and ethyl vanillin. S* S se :o go•
AU16309/92A 1991-05-17 1992-05-15 Dentifrice composition Ceased AU648892B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9110721 1991-05-17
GB919110721A GB9110721D0 (en) 1991-05-17 1991-05-17 Dentifrice compositions

Publications (2)

Publication Number Publication Date
AU1630992A AU1630992A (en) 1992-11-19
AU648892B2 true AU648892B2 (en) 1994-05-05

Family

ID=10695184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16309/92A Ceased AU648892B2 (en) 1991-05-17 1992-05-15 Dentifrice composition

Country Status (11)

Country Link
US (1) US5258173A (en)
EP (1) EP0514966B1 (en)
JP (1) JPH0713009B2 (en)
AT (1) ATE124862T1 (en)
AU (1) AU648892B2 (en)
BR (1) BR9201852A (en)
CA (1) CA2068606C (en)
DE (1) DE69203391T2 (en)
ES (1) ES2075594T3 (en)
GB (1) GB9110721D0 (en)
ZA (1) ZA923553B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374417A (en) * 1991-10-17 1994-12-20 Colgate Palmolive Company Desensitizing dentifrice
GB9122909D0 (en) * 1991-10-29 1991-12-11 Unilever Plc Toothpaste composition
WO1994027565A1 (en) * 1993-05-28 1994-12-08 Hawe Neos Dental Tin fluoride preparation for the care of the teeth
CA2169361A1 (en) * 1993-08-13 1995-02-23 Andrew Robert Gallopo Tooth whitening preparations
US5833952A (en) * 1993-09-16 1998-11-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Oral compositions
US5338537A (en) * 1993-10-05 1994-08-16 The Procter & Gamble Company Oral compositions
US5837222A (en) * 1994-06-10 1998-11-17 Cloonan; Richard A. Liquid dental cleaning solution
US5573398A (en) * 1994-06-10 1996-11-12 Towle; Lawrence E. Dental hygiene device and cleaning solution
US6224376B1 (en) 1994-06-10 2001-05-01 Richard A. Cloonan Dental cleaning liquid and gel
US5578293A (en) * 1994-12-06 1996-11-26 Colgate Palmolive Company Oral compositions containing stabilized stannous compounds having antiplaque and antitartar efficacy
ATE305290T1 (en) * 1999-03-12 2005-10-15 Pfizer Prod Inc ORAL PREPARATIONS FOR REDUCING THE SENSITIVITY OF THE DENTAL NERVE AND DENTAL CONTAINING POTASSIUM SALTS
MXPA02004783A (en) * 1999-11-12 2002-08-30 Procter & Gamble Improved dual phase stannous oral compositions.
EP1267813A2 (en) * 2000-03-31 2003-01-02 Henkel Kommanditgesellschaft auf Aktien Use of protease inhibitors in cosmetics and pharmacy
PE20020102A1 (en) * 2000-06-30 2002-03-06 Procter & Gamble TOPICAL ORAL COMPOSITION INCLUDING A MODULATING AGENT OF THE HOST RESPONSE TO PERIODONTAL PATHOGENS
CN1287803C (en) * 2000-06-30 2006-12-06 宝洁公司 Promoting whole body health
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
FR2838339B1 (en) * 2002-04-12 2005-06-24 Univ Angers POLYPHOSPHONATE DERIVATIVES FOR DENTIFRING COMPOSITIONS
AU2003303923A1 (en) * 2002-11-22 2004-09-06 Unilever Plc Oral care composition comprising an antimicrobial agent
FR2878248B1 (en) * 2004-11-22 2007-01-12 Surfactis Technologies Soc Par BISPHOSPHONIC COMPOUNDS FOR PREVENTING OR LIMITING FIXATION OF MACROMOLECULES, MICROORGANISMS AND BIOFILM ON SOLID SURFACES, ESPECIALLY METALLIC OR MINERAL
JP2008523074A (en) * 2004-12-07 2008-07-03 アクセス ビジネス グループ インターナショナル エルエルシー Method for removing nitric oxide and oxygen species with antioxidant fragrances
US20070092454A1 (en) * 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
US8865192B2 (en) * 2006-07-07 2014-10-21 The Procter & Gamble Co Flavor oils with reduced sulfur content and use in oral care compositions
GB0822434D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Novel use
ES2407858T3 (en) 2010-04-07 2013-06-14 Gaba International Holding Ag Composition for oral care comprising stannous ions and nitrate.
EP2555828B1 (en) * 2010-04-09 2017-07-19 Unilever PLC, a company registered in England and Wales under company no. 41424 Oral care compositions
EP2753624B1 (en) * 2011-09-09 2017-11-08 GABA International Holding GmbH Stable compositions and methods for preparing the same
CN104721066B (en) 2013-12-19 2018-08-07 高露洁-棕榄公司 Make the method for rutin solubilising with multi-hydroxy alkyl alcohol
CA2976123A1 (en) 2015-07-01 2017-01-05 Colgate-Palmolive Company Oral care compositions and methods of use
US20180289599A1 (en) * 2015-10-08 2018-10-11 Colgate-Palmolive Company Oral Care Compositions
CN108472209B (en) 2015-12-30 2021-06-25 高露洁-棕榄公司 Personal care compositions
CN109069391B (en) 2015-12-30 2022-02-11 高露洁-棕榄公司 Oral care compositions
WO2017117379A1 (en) 2015-12-30 2017-07-06 Colgate-Palmolive Company Oral care compositions
RU2731096C2 (en) 2015-12-30 2020-08-28 Колгейт-Палмолив Компани Compositions for personal hygiene
US10617620B2 (en) 2016-06-24 2020-04-14 Colgate-Palmolive Company Oral care compositions and methods of use
US11154468B2 (en) * 2016-12-21 2021-10-26 Colgate-Palmolive Company Oral care compositions and methods of use
CA3123447A1 (en) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Oral care compositions
WO2020264570A1 (en) * 2019-06-28 2020-12-30 The Procter & Gamble Company Oral care compositions comprising tin ions
WO2020258204A1 (en) * 2019-06-28 2020-12-30 The Procter & Gamble Company Oral care compositions comprising tin ions
US11135143B2 (en) 2020-06-25 2021-10-05 The Procter & Gamble Company Oral care compositions comprising tin ions
CA3144448A1 (en) 2019-06-28 2020-12-30 Arif Ali Baig Oral care compositions comprising tin ions
BR112021024290A2 (en) 2019-06-28 2022-01-11 Procter & Gamble Toothpaste compositions comprising tin ions
BR112021025918A2 (en) 2019-07-01 2022-05-03 Colgate Palmolive Co Compositions and methods for oral hygiene
US20240050333A1 (en) * 2020-12-21 2024-02-15 Colgate-Palmolive Company Oral Care Compositions Comprising Stannous Pyrophosphate and a Water-Soluble Alkali Metal Polyphosphate, and Methods
US12104021B2 (en) 2021-02-22 2024-10-01 The Procter & Gamble Company Recycling of superabsorbent fibers with an extensional flow device
US20240180799A1 (en) * 2022-12-05 2024-06-06 Colgate-Palmolive Company Oral Care Compositions Containing Stannous Ion Source

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE544763A (en) * 1955-02-09
FR1295306A (en) * 1956-04-25 1962-06-08 Procter & Gamble Improvements to toothpaste compositions
BE556526A (en) * 1956-04-25
GB845611A (en) * 1957-01-15 1960-08-24 Hedley Thomas & Co Ltd Improvements in and relating to toothpastes
US3152155A (en) * 1960-01-04 1964-10-06 Dow Chemical Co Insoluble chelates of divalent tin, germanium, and lead
US3925543A (en) * 1973-11-01 1975-12-09 Colgate Palmolive Co Antibacterial oral compositions containing preservative-antioxidants
GB1514469A (en) * 1974-08-01 1978-06-14 Beecham Group Ltd Oral hygiene compositions
US3887701A (en) * 1974-11-01 1975-06-03 Colgate Palmolive Co Antibacterial oral compositions containing preservative-antioxidants
JPS6043324B2 (en) * 1977-10-20 1985-09-27 ライオン株式会社 Oral composition
JPS55100310A (en) * 1979-01-26 1980-07-31 Lion Corp Fluorine-containing preparation
US4364794A (en) * 1980-01-07 1982-12-21 Ecodyne Corporation Liquid concentration apparatus
US4411885A (en) * 1980-09-30 1983-10-25 Barels Ronald R Vitamin E oil based dentifrice
JPS58213706A (en) * 1982-06-08 1983-12-12 Lion Corp Composition for oral cavity
JPS6048920A (en) * 1983-08-29 1985-03-16 Ajinomoto Co Inc Oral agent containing dipeptide sweetener
JPS6075418A (en) * 1983-10-03 1985-04-27 Lion Corp Composition for oral cavity application
JPS6137720A (en) * 1984-07-31 1986-02-22 Lion Corp Composition for oral cavity
JPS62161715A (en) * 1986-01-07 1987-07-17 Kao Corp Dentifrice agent
JPH0788292B2 (en) * 1986-09-05 1995-09-27 ライオン株式会社 Oral composition
US5094841A (en) * 1988-07-05 1992-03-10 The Trustees Of Columbia University In The City Of New York Gel for optimum release of fluoride with antibacterial capability for use in the prevention of caries of root surface
GB8920796D0 (en) * 1989-09-14 1989-11-01 Rolla Gunnar Dentifrice compositions
GB8922594D0 (en) * 1989-10-06 1989-11-22 Unilever Plc Oral compositions

Also Published As

Publication number Publication date
ES2075594T3 (en) 1995-10-01
CA2068606A1 (en) 1992-11-18
GB9110721D0 (en) 1991-07-10
JPH0713009B2 (en) 1995-02-15
EP0514966A2 (en) 1992-11-25
EP0514966B1 (en) 1995-07-12
DE69203391T2 (en) 1995-11-30
DE69203391D1 (en) 1995-08-17
EP0514966A3 (en) 1992-12-09
BR9201852A (en) 1993-01-05
US5258173A (en) 1993-11-02
CA2068606C (en) 1996-10-15
JPH05148125A (en) 1993-06-15
ATE124862T1 (en) 1995-07-15
ZA923553B (en) 1993-11-15
AU1630992A (en) 1992-11-19

Similar Documents

Publication Publication Date Title
AU648892B2 (en) Dentifrice composition
US5188820A (en) Method of inhibiting plaque on teeth by applying an oral composition
US5833952A (en) Oral compositions
US5094842A (en) Oral compositions
AU629317B2 (en) Oral composition containing strontium and potassium for dentine hypersensitivity
US4259316A (en) Oral composition for caries prophylaxis
US4370314A (en) Oral composition containing antibacterial agent
US4273759A (en) Antibacterial oral composition
US3932606A (en) Dentifrice
US4272512A (en) Antigingivitis composition
WO2003022256A3 (en) Stable oral care compositions comprising chlorite
US4272513A (en) Stabilized oral composition
EP0510158B1 (en) Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and metal salts
US4309410A (en) Non-staining antigingivitis composition
US4774078A (en) Stable antiplaque dentifrice based on hexetidine, zinc ion and fluoride
JPH02286613A (en) New composition
EP0426213B1 (en) Oral compositions
JP4615603B2 (en) Oral composition containing morin
WO1997040812A1 (en) Enhanced zinc containing oral composition
JPH10139641A (en) Oral cavity composition

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired